Bausch + Lomb’s BL1332 eye‑pain drug misses Phase 2 primary endpoint
Bausch + Lomb reported that its Phase 2 study of BL1332, a topical TRPV1 antagonist for post‑surgical ocular pain, failed to achieve statistical significance on the primary pain‑intensity endpoint over 24 hours. The least‑squares mean differences versus vehicle were –11.5 for the 0.30 % dose and –9.0 for the 0.15 % dose. Both doses showed numerically greater pain relief and faster corneal healing, and the drug was well tolerated. The company said it will discuss the results with the FDA and consider Phase 3 planning.
Why it matters
The company expects the FDA discussion to shape the design of any future late‑stage trial, which could affect the timeline for a potential new ocular‑pain therapy. The missed primary endpoint triggered a drop in BLCO shares in after‑hours trading.
Key facts
- 1The randomized, double‑masked Phase 2 study enrolled 129 adults undergoing photorefractive keratectomy. stratfordbeaconherald.com
- 2The primary endpoint – sum of pain intensity differences over 24 hours – was not met. stratfordbeaconherald.com
- 3Least‑squares mean difference versus vehicle was –11.5 for BL1332 0.30 % and –9.0 for BL1332 0.15 %. stratfordbeaconherald.com
- 4At six hours post‑surgery, complete pain relief was reported by 14.0 % (0.30 %) and 14.6 % (0.15 %) of patients versus 3.7 % with vehicle. stratfordbeaconherald.com
- 5Treatment‑emergent adverse events occurred in 6.0 % (0.30 %), 13.7 % (0.15 %) and 14.8 % (vehicle) of participants. stratfordbeaconherald.com
- 6BLCO shares fell 1.8 % in after‑hours trading following the announcement. investing.com
Open questions
- Share price decline reported as 1.8 % and nearly 4 % in after‑hours trading.
Summary written by AlphAI AI Desk from 6 of 6 sources. Not investment advice. Figures are as stated by the linked sources.